Spire Wealth Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Spire Wealth Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30	Closed	-$1.15K	–	2500
2023 Q2	$1.15K	Hold	30	–	–	﹤0.01%	2291
2023 Q1	$695	Buy	+30	New	+$715	﹤0.01%	2433

Spire Wealth Management's KDNY Position: Q3 2023 in Review

Spire Wealth Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 30 shares — an estimated $1.15K sold.

Spire Wealth Management first reported a position in KDNY in Q1 2023 and held it in 2 quarters. The position peaked at $1.15K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Spire Wealth Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Spire Wealth Management sold 30 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.15K.
Spire Wealth Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
Spire Wealth Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.15K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Spire Wealth Management's 13F filing for Q3 2023, filed 8 Nov 2023.